JAC Advance Access published online on January 14, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg095
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Faculty of Veterinary
Medicine, Department of Clinical Veterinary Sciences, PO Box 57,
Helsinki
* Corresponding author. E-mail: jaana.harmoinen{at}helsinki.fi.
Received 8 August 2002
; revised 29 October 2002
; accepted 20 November 2002
Antibiotics can cause severe alterations in the gut
microflora and promote diarrhoea and overgrowth of pathogenic bacteria.
The present study investigated the potency of targeted recombinant
Keywords: Enzymic degradation of a
-lactam
antibiotic, ampicillin, in the gut:
a novel treatment modality
2 Institute of Biomedicine/Pharmacology,
PO Box 63, University of Helsinki, FIN-00014 Helsinki
3 Ipsat Therapies Ltd, Sinimäentie
10B, FIN-02630 Espoo, Finland
-lactamase (TRBL) to degrade a
-lactam antibiotic in the jejunum of
fistula-operated beagles. We used different peroral doses of purified
-lactamase (PenP) of Bacillus
licheniformis in enteric-coated pellets together with intravenous
ampicillin. Serum and jejunal samples were collected for ampicillin
and
-lactamase analysis. A dose-response
effect of TRBL on ampicillin concentrations in the jejunal samples
could be observed. The highest doses applied decreased the jejunal
ampicillin concentrations to undetectable levels. In the serum samples,
the ampicillin concentrations were not affected by the
-lactamase
dose used. Our results indicate that it may be possible to evolve
a targeted treatment to degrade
-lactam
antibiotics intestinally and, thus, decrease antibiotic-induced
adverse effects on the gut microflora.
-lactamase,
-lactams, jejunum, microflora
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A.-M. Tarkkanen, T. Heinonen, R. Jogi, S. Mentula, M. E. van der Rest, C. J. Donskey, T. Kemppainen, K. Gurbanov, and C. E. Nord P1A Recombinant {beta}-Lactamase Prevents Emergence of Antimicrobial Resistance in Gut Microflora of Healthy Subjects during Intravenous Administration of Ampicillin Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2455 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Harmoinen, S. Mentula, M. Heikkila, M. van der Rest, P. J. Rajala-Schultz, C. J. Donskey, R. Frias, P. Koski, N. Wickstrand, H. Jousimies-Somer, et al. Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance Antimicrob. Agents Chemother., January 1, 2004; 48(1): 75 - 79. [Abstract] [Full Text] [PDF] |
||||
